Growth factors are very promising molecules for the treatment of skin wounds. However, their translation to clinical use has been seriously limited, facing issues related to safety and cost-effectiveness. These problems may derive from the fact that growth factors are used at vastly supra-physiological levels without optimized delivery systems.
Recent Advances:
The extracellular matrix (ECM) plays a fundamental role in coordinating growth factor signaling. Therefore, understanding the mechanisms by which the ECM modulates growth factor activity is key for designing efficient growth factor-based therapies. Recently, several growth factor-binding domains have been discovered within various ECM proteins, and growth factor delivery systems integrating these ECM growth factor-binding domains showed promising results in animal models of skin wound healing. Moreover, a novel strategy consisting of engineering growth factors to target endogenous ECM could substantially enhance their efficacy, even when used at low doses.
Critical Issues:
Optimal delivery of growth factors often requires complex engineered biomaterial matrices, which can face regulatory issues for clinical translation. To simplify delivery systems and render strategies more applicable, growth factors can be engineered to optimally function with clinically approved biomaterials or with endogenous ECM present at the delivery site.
Future Directions:
Further development and clinical trials will reveal whether growth factor-based therapies can be used as main therapeutic approaches for skin wound healing. The future impact of these therapies will depend on our capacity to deliver growth factors more precisely, to improve efficacy, safety, and cost-effectiveness.
Get full access to this article
View all access options for this article.
References
1.
WerdinF, TennenhausM, SchallerHE. Evidence-based management strategies for treatment of chronic wounds. Eplasty, 2009; 8:26.
2.
SenCK, GordilloGM, RoyS, et al.Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair Regen, 2009; 17:763–771.
MouraLIF, DiasAMA, CarvalhoE, de SousaHC. Recent advances on the development of wound dressings for diabetic foot ulcer treatment—a review. Acta Biomater, 2013; 9:7093–7114.
6.
GoldmanR. Growth factors and chronic wound healing: past, present, and future. Adv Skin Wound Care, 2004; 17:24–35.
7.
CarterK. Growth factors: the wound healing therapy of the future?. Br J Commun Nurs, 2003; 8:S15-6, S18-9, S22-3.
8.
LeeK, SilvaEA, MooneyDJ. Growth factor delivery-based tissue engineering: general approaches and a review of recent developments. J R Soc Interface, 2011; 8:153–170.
9.
RiceJJ, MartinoMM, De LaporteL, TortelliF, BriquezPS, HubbellJA. Engineering the regenerative microenvironment with biomaterials. Adv Healthc Mater, 2013; 2:57–71.
10.
MartinoMM, BriquezPS, GucE, et al.Growth factors engineered for super-affinity to the extracellular matrix enhance tissue healing. Science, 2014; 343:885–888.
11.
BennettSP, GriffithsGD, SchorAM, LeeseGP, SchorSL. Growth factors in the treatment of diabetic foot ulcers. Br J Surg, 2003; 90:133–146.
12.
Demidova-RiceTN, HamblinMR, HermanIM. Acute and impaired wound healing: pathophysiology and current methods for drug delivery, part 2: role of growth factors in normal and pathological wound healing: therapeutic potential and methods of delivery. Adv Skin Wound Care, 2012; 25:349–370.
13.
BuchbergerB, FollmannM, FreyerD, HuppertzH, EhmA, WasemJ. The importance of growth factors for the treatment of chronic wounds in the case of diabetic foot ulcers. GMS Health Technol Assess, 2010; 6:Doc12.
WernerS, GroseR. Regulation of wound healing by growth factors and cytokines. Physiol Rev, 2003; 83:835–870.
16.
BarrientosS, StojadinovicO, GolinkoMS, BremH, Tomic-CanicM. Growth factors and cytokines in wound healing. Wound Repair Regen, 2008; 16:585–601.
17.
TraversaB, SussmanG. The role of growth factors, cytokines and proteases in wound management. AWMA J, 2001; 9:161–167.
18.
MartinoMM, HubbellJA. The 12th-14th type III repeats of fibronectin function as a highly promiscuous growth factor-binding domain. FASEB J, 2010; 24:4711–4721.
19.
De LaporteL, RiceJJ, TortelliF, HubbellJA. Tenascin C promiscuously binds growth factors via its fifth fibronectin type III-like domain. PLoS One, 2013; 8:e62076.
20.
UptonZ, CuttleL, NobleA, et al.Vitronectin: growth factor complexes hold potential as a wound therapy approach. J Invest Dermatol, 2008; 128:1535–1544.
21.
SchultzGS, LadwigG, WysockiA. Extracellular matrix: review of its roles in acute and chronic wounds. World Wide Wounds 2005. www.worldwidewounds.com/2005/august/Schultz/Extrace-Matric-Acute-Chronic-Wounds.html.
22.
AgrenMS, WerthenM. The extracellular matrix in wound healing: a closer look at therapeutics for chronic wounds. Int J Low Extrem Wounds, 2007; 6:82–97.
23.
KumarV, AbbasAK, FaustoN, AsterJC. Robbins and Cotran Pathologic Basis of Disease, Professional Edition. Philadelphia, PA: Elsevier Health Sciences. 2009.
24.
ShuttleworthL, BlackRA. Deposition of elastic fibres in a murine cutaneous wound healing model. Int J Exp Pathol, 2005; 86:A68.
25.
HumphriesJD. Integrin ligands at a glance. J Cell Sci, 2006; 119:3901–3903.
26.
SchultzGS, WysockiA. Interactions between extracellular matrix and growth factors in wound healing. Wound Repair Regen, 2009; 17:153–162.
27.
SchönherrE, HausserH. Extracellular matrix and cytokines: a functional unit. Dev Immunol, 2000; 7:89–101.
28.
CapilaI, LinhardtRJ. Heparin–protein interactions. Angew Chem Int Ed, 2002; 41:390–412.
29.
MacriL, SilversteinD, ClarkRAF. Growth factor binding to the pericellular matrix and its importance in tissue engineering. Adv Drug Deliv Rev, 2007; 59:1366–1381.
30.
MartinoMM, BriquezPS, RangaA, LutolfMP, HubbellJA. Heparin-binding domain of fibrin(ogen) binds growth factors and promotes tissue repair when incorporated within a synthetic matrix. Proc Natl Acad Sci U S A, 2013; 110:4563–4568.
31.
HynesRO. The extracellular matrix: not just pretty fibrils. Science, 2009; 326:1216–1219.
MartinoMM, TortelliF, MochizukiM, et al.Engineering the growth factor microenvironment with fibronectin domains to promote wound and bone tissue healing. Sci Transl Med, 2011; 3:100ra89.
Demidova-RiceTN, HamblinMR, HermanIM. Acute and impaired wound healing: pathophysiology and current methods for drug delivery, part 1: normal and chronic wounds: biology, causes, and approaches to care. Adv Skin Wound Care, 2012; 25:304–314.
39.
FerraroB, CruzYL, CoppolaD, HellerR. Intradermal delivery of plasmid VEGF(165) by electroporation promotes wound healing. Mol Ther, 2009; 17:651–657.
40.
LeeP-Y, LiZ, HuangL. Thermosensitive hydrogel as a Tgf-β1 gene delivery vehicle enhances diabetic wound healing. Pharm Res, 2003; 20:1995–2000.
41.
BreitbartAS, LaserJ, ParrettB, et al.Accelerated diabetic wound healing using cultured dermal fibroblasts retrovirally transduced with the platelet-derived growth factor B gene. Ann Plast Surg, 2003; 51:409.
42.
LutolfMP, HubbellJA. Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat Biotechnol, 2005; 23:47–55.
43.
AroraNS, RamanayakeT, RenY-F, RomanosGE. Platelet-rich plasma: a literature review. Implant Dent, 2009; 18:303–310.
44.
ShevchenkoRV, JamesSL, JamesSE. A review of tissue-engineered skin bioconstructs available for skin reconstruction. J R Soc Interface, 2010; 7:229–258.
45.
LiuY, CaiS, ShuXZ, ShelbyJ, PrestwichGD. Release of basic fibroblast growth factor from a crosslinked glycosaminoglycan hydrogel promotes wound healing. Wound Repair Regen, 2007; 15:245–251.
46.
UptonZ, WallaceHJ, ShooterGK, et al.Human pilot studies reveal the potential of a vitronectin: growth factor complex as a treatment for chronic wounds. Int Wound J, 2011; 8:522–532.
47.
ZhuJ, ClarkRAF. Fibronectin at select sites binds multiple growth factors and enhances their activity: expansion of the collaborative ECM-GF paradigm. J Invest Dermatol, 2014; 134:895–901.
48.
KimSH, TurnbullJ, GuimondS. Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. J Endocrinol, 2011; 209:139–151.
49.
GiancottiFG, TaroneG. Positional control of cell fate through joint integrin/receptor protein kinase signaling. Annu Rev Cell Dev Biol, 2003; 19:173–206.
50.
LinF, RenX-D, PanZ, et al.Fibronectin growth factor-binding domains are required for fibroblast survival. J Invest Dermatol, 2011; 131:84–98.
51.
WijelathES, RahmanS, NamekataM, et al.Heparin-II domain of fibronectin is a vascular endothelial growth factor-binding domain: enhancement of VEGF biological activity by a singular growth factor/matrix protein synergism. Circ Res, 2006; 99:853–860.
52.
ComoglioPM, BoccaccioC, TrusolinoL. Interactions between growth factor receptors and adhesion molecules: breaking the rules. Curr Opin Cell Biol, 2003; 15:565–571.
53.
EhrbarM, DjonovVG, SchnellC, et al.Cell-demanded liberation of VEGF121 from fibrin implants induces local and controlled blood vessel growth. Circ Res, 2004; 94:1124–1132.
54.
TraubS, MorgnerJ, MartinoMM, et al.The promotion of endothelial cell attachment and spreading using FNIII10 fused to VEGF-A165. Biomaterials, 2013; 34:5958–5968.
55.
SacchiV, MittermayrR, HartingerJ, et al.Long-lasting fibrin matrices ensure stable and functional angiogenesis by highly tunable, sustained delivery of recombinant VEGF164. Proc Natl Acad Sci U S A, 2014; 111:6952–6957.
56.
TokunouT, MillerR, PatwariP, et al.Engineering insulin-like growth factor-1 for local delivery. FASEB J, 2008; 22:1886–1893.
57.
AcharRAN, SilvaTC, AcharE, MartinesRB, MachadoJLM. Use of insulin-like growth factor in the healing of open wounds in diabetic and non-diabetic rats. Acta Cir Bras, 2014; 29:125–131.
58.
ChenF-M, ZhangM, WuZ-F. Toward delivery of multiple growth factors in tissue engineering. Biomaterials, 2010; 31:6279–6308.
59.
CarmelietP. Angiogenesis in health and disease. Nat Med, 2003; 9:653–660.
60.
HerbertSP, StainierDYR. Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nat Rev Mol Cell Biol, 2011; 12:551–564.
61.
HaoX, SilvaEA, Månsson-BrobergA, et al.Angiogenic effects of sequential release of VEGF-A165 and PDGF-BB with alginate hydrogels after myocardial infarction. Cardiovasc Res, 2007; 75:178–185.
62.
RuvinovE, LeorJ, CohenS. The promotion of myocardial repair by the sequential delivery of IGF-1 and HGF from an injectable alginate biomaterial in a model of acute myocardial infarction. Biomaterials, 2011; 32:565–578.
